Study highlights the patient heterogeneity in atopic dermatitis and demonstrates the promises of personalized treatment

Researchers investigated endotype-phenotype associations in atopic dermatitis (AD) beyond its general clinical severity.

Ketamine’s rapid impact on depression linked to immune system pathways

Study reveals ketamine’s potent anti-inflammatory effects on neurological disorders, showing promise for treating major depressive disorder through modulation of neuroimmune pathways.

April 15, 2024

Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D – Biotech Investments

EQS-News: Formycon AG / Key word(s): Scientific publication/Study results Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal

October 17, 2024

Gilead won’t acquire checkpoint oncology biotech Tizona

Gilead has now passed on two biotech buyout options that it forged in summer 2020. The large drugmaker will not acquire Tizona Therapeutics, a fellow

February 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.